Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Faeth Therapeutics, Inc.FTH · Entity 5029 | PAO | July 21, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Faeth Therapeutics, Inc.
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance-Based Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.37 · Expires 2036-07-20 | Direct | 30,824 |
Reported balance
After 2026-07-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-21 · Grant · Acquired 30,824 · Balance 30,824 F1: Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety. F2: In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety.
F2: In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2026 Filed Jul 23, 2026 20:15 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | GrantPerformance-Based Stock Option (right to buy) · Derivative | 30,824 | $0.00 Strike: $28.37 | $0.00 |
DisclosureSEC source: 0002038400-26-000004 · form4-07232026_040703.xml · derivative · entry 1 Craver Josiah · CIK 0002038400 · PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,824 Underlying: Common Stock · 30,824 shares Expires 2036-07-20 F1 · derivative.exercise_date: Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety. F2 · derivative.exercise_date: In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety. Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 21:18 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $29.89 | $0.00 |
DisclosureSEC source: 0002038400-26-000001 · form4-04142026_090421.xml · derivative · entry 1 Craver Josiah · CIK 0002038400 · PFO & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-04-09 F1 · derivative.exercise_date: 25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the date of grant, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 14, 2025 Filed Feb 14, 2025 23:04 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001415889-25-004226 · form4-02142025_110254.xml · derivative · entry 1 Craver Josiah · CIK 0002038400 · Principal Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 14, 2026, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 21:15 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001415889-24-030068 · form4-12232024_041225.xml · derivative · entry 1 Craver Josiah · CIK 0002038400 · Principal Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-12-19 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on December 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.